Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Антигистаминные препараты: современные критерии выбора
Антигистаминные препараты: современные критерии выбора
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Горячкина Л.А., Передкова Е.В. Антигистаминные препараты. 2004.
2. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт, 1998.
3. Ненашева Н. Астма и аллергия. Врач. 2008; 11: 15–9.
4. Саймонс Э. Отчет о докладе: Антигистаминные препараты. Не навреди. Практика педиатра. От исследований к практике. 2009; с. 20–2.
5. Томилова А.Ю., Намазова Л.С, Кузенкова Л.Н., Маслова О.И. Коррекция нарушений когнитивной сферы у детей с аллергическим ринитом. Вопросы современной педиатрии. 2007; 2: 123–7.
6. Agrawal et al. Allergy 2000; 55: 276.
7. Agrawal. Clin Exp Allergy 2004; 34: 1342.
8. Bousquet J et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003; 58: 192.
9. Bousquet J, Bindslev-Jensen C, Canonica GW. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004; 59 (Suppl. 77): 4–16.
10. Bousquet J, Khaltaev N, Cruz A et al. Allergic rhinitis and its impact on asthma (ARIA). Allergy 2008; 63 (Suppl. 86): 9–160.
11. Boyle J, Erilesson M et al. Allergy medication in Japanese volunteers: treatment effect of single doses on natural sleep architecture and next day residual effects. Curr Med Res Opin 2006; 22: 1343–51.
12. Church M, Maurer M, Simons F et al. Risk of first – generation H1-antihistamines: a GA2LEN position paper. Allergy 2010; 65: 459–66.
13. Cockburn M, Bailit H et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41: 948–53.
14. Daly A. Allergy 2001; 56 (Suppl. 68): 79.
15. Garoia-Gea C, Martinez-Colomer J et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of histamine, a new H1 antihistamine a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008; 28: 675–85.
16. Genovese et al. Clin Exp Allergy 1997; 27: 559.
17. Golightly L, Greos L. Second-generation antihistamines: actions efficacy in the management of allergic disorders. Drugs 2005; 65 (3): 341–84.
18. Juniper EF, Stahl E, Doty R, Simons EF. Clinical outcomes and adverse effect monitoringin allergic rhinitis J Allergy Clin Immunol 2005; 3(Suppl. 1): 390–413.
19. Kay G, Berman B et al. Initial and steady- effects of diphenhydramine and loratadine on sedation, cognition, mood and psychomotor performance. Arch Intern Med 1997; 157: 2350–6.
20. Kleine-Tebbe et al. J Allergy Clin Immunol 1994; 93: 494.
21. Kreutner et al. Arzneimittelforschung 2000; 50: 345.
22. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti- inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489–98.
23. Lippert et al. Exp Dermatol 1995; 4: 272.
24. McDonagh M et al. Drug Class Review: Newer Antihistamines. Final Report Update 2010; 1–72.
25. Molet et al. Clin Exp Allergy 1997; 27 (1167): 34.
26. Nine JS, Rund CR. Fatality from diphenhydramine monointoxication: a case report and review of the infant, pediatric, and adultliterature. Am J Forensic Med Pathol 2006; 27: 36–41.
27. Paton D, Webster D et al. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985; 10: 477–97.
28. Richurdson G, Roehrs T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002; 22: 511–5.
29. Ring J. Int J Dermatol 2001.
30. Shamsi Z, Hindmarch T. Sedation and antihistamines: a review of inter-drug differences using proportional impairment rations. Hum Psychopharmocol 2000; 15: 3–30.
31. Schroder et al. Clin Exp Allergy 2001; 31: 1369.
32. Simons EF et al. Advanced in H1-antihistamines. N Engl J Med 2004; 351: 2203–17.
33. Strenkoski-Nix LC, Ermer J et al. Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects. Am J Health Syst Pharm 2000; 57: 1499–500.
34. Source: Summaries of Product Characteristics, Avaiable at: http://emc.medicines.org.uk
35. Tashiro M et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepness, and brain histamine H1-receptor Occupancy Using C-Doxepin Positron Emission Tomography. J Clin Pharmacol 2004; 44: 890–900.
36. Tashiro M, Mochizuki H, Iwabuchi K et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1-receptors in human brain. Life Sci 2002; 72 (4–5): 40–14. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1-receptors in human brain.
37. Vignola et al. Allergy 1995; 50: 200.
38. Weiler J, Bloomfiekl J et al. Effectsof fexofenadine, difenhydramine and alcohol on driving performance. A randomized, placebo-controlled trial in the Lowa driving simulator. Ann Inter Med 2000; 132: 354–63.
2. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт, 1998.
3. Ненашева Н. Астма и аллергия. Врач. 2008; 11: 15–9.
4. Саймонс Э. Отчет о докладе: Антигистаминные препараты. Не навреди. Практика педиатра. От исследований к практике. 2009; с. 20–2.
5. Томилова А.Ю., Намазова Л.С, Кузенкова Л.Н., Маслова О.И. Коррекция нарушений когнитивной сферы у детей с аллергическим ринитом. Вопросы современной педиатрии. 2007; 2: 123–7.
6. Agrawal et al. Allergy 2000; 55: 276.
7. Agrawal. Clin Exp Allergy 2004; 34: 1342.
8. Bousquet J et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003; 58: 192.
9. Bousquet J, Bindslev-Jensen C, Canonica GW. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004; 59 (Suppl. 77): 4–16.
10. Bousquet J, Khaltaev N, Cruz A et al. Allergic rhinitis and its impact on asthma (ARIA). Allergy 2008; 63 (Suppl. 86): 9–160.
11. Boyle J, Erilesson M et al. Allergy medication in Japanese volunteers: treatment effect of single doses on natural sleep architecture and next day residual effects. Curr Med Res Opin 2006; 22: 1343–51.
12. Church M, Maurer M, Simons F et al. Risk of first – generation H1-antihistamines: a GA2LEN position paper. Allergy 2010; 65: 459–66.
13. Cockburn M, Bailit H et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41: 948–53.
14. Daly A. Allergy 2001; 56 (Suppl. 68): 79.
15. Garoia-Gea C, Martinez-Colomer J et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of histamine, a new H1 antihistamine a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008; 28: 675–85.
16. Genovese et al. Clin Exp Allergy 1997; 27: 559.
17. Golightly L, Greos L. Second-generation antihistamines: actions efficacy in the management of allergic disorders. Drugs 2005; 65 (3): 341–84.
18. Juniper EF, Stahl E, Doty R, Simons EF. Clinical outcomes and adverse effect monitoringin allergic rhinitis J Allergy Clin Immunol 2005; 3(Suppl. 1): 390–413.
19. Kay G, Berman B et al. Initial and steady- effects of diphenhydramine and loratadine on sedation, cognition, mood and psychomotor performance. Arch Intern Med 1997; 157: 2350–6.
20. Kleine-Tebbe et al. J Allergy Clin Immunol 1994; 93: 494.
21. Kreutner et al. Arzneimittelforschung 2000; 50: 345.
22. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti- inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489–98.
23. Lippert et al. Exp Dermatol 1995; 4: 272.
24. McDonagh M et al. Drug Class Review: Newer Antihistamines. Final Report Update 2010; 1–72.
25. Molet et al. Clin Exp Allergy 1997; 27 (1167): 34.
26. Nine JS, Rund CR. Fatality from diphenhydramine monointoxication: a case report and review of the infant, pediatric, and adultliterature. Am J Forensic Med Pathol 2006; 27: 36–41.
27. Paton D, Webster D et al. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985; 10: 477–97.
28. Richurdson G, Roehrs T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002; 22: 511–5.
29. Ring J. Int J Dermatol 2001.
30. Shamsi Z, Hindmarch T. Sedation and antihistamines: a review of inter-drug differences using proportional impairment rations. Hum Psychopharmocol 2000; 15: 3–30.
31. Schroder et al. Clin Exp Allergy 2001; 31: 1369.
32. Simons EF et al. Advanced in H1-antihistamines. N Engl J Med 2004; 351: 2203–17.
33. Strenkoski-Nix LC, Ermer J et al. Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects. Am J Health Syst Pharm 2000; 57: 1499–500.
34. Source: Summaries of Product Characteristics, Avaiable at: http://emc.medicines.org.uk
35. Tashiro M et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepness, and brain histamine H1-receptor Occupancy Using C-Doxepin Positron Emission Tomography. J Clin Pharmacol 2004; 44: 890–900.
36. Tashiro M, Mochizuki H, Iwabuchi K et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1-receptors in human brain. Life Sci 2002; 72 (4–5): 40–14. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1-receptors in human brain.
37. Vignola et al. Allergy 1995; 50: 200.
38. Weiler J, Bloomfiekl J et al. Effectsof fexofenadine, difenhydramine and alcohol on driving performance. A randomized, placebo-controlled trial in the Lowa driving simulator. Ann Inter Med 2000; 132: 354–63.
Авторы
Д.С.Фомина, О.С.Дробик, Л.А.Горячкина
ГБОУ ДПО Российская медицинская академия последипломного образования, Москва
ГБОУ ДПО Российская медицинская академия последипломного образования, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.
